Akademik Veri Yönetim Sistemi
Üstündağ S., Kumbasar A., Pıtt B., George B., Agarwal R., Anker S., et al.
Diğer Ülkelerin Sanayi Kuruluşları Tarafından Desteklenmiş Proje, 2016 - 2020
The primary objective of this study was to demonstrate whether, in addition to standard of care, finerenone is superior to placebo in delaying the progression of kidney disease, as measured by the composite endpoint of time to first occurrence of kidney failure, a sustained decrease of estimated glomerular filtration rate (eGFR) ≥40% from baseline over at least 4 weeks, or renal death.